ClinicalTrials.gg
RecruitingNCT05336695Updated Oct 30, 2025

Assess Fibrin in Brains With AD/ADRD

A Phase 1/2 interventional study of PET/MR Imaging and 64Cu-FBP8 in Alzheimer Disease and Dementia of Alzheimer Type, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 55 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Massachusetts General Hospital · Phase 1/2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Alzheimer Disease by Massachusetts General Hospital — 9 open to participants now, 10 under way, none of them phase 3. Alzheimer Disease · Massachusetts General Hospital.

Planned enrollment
10th of 25
30 · median 20
Started
2022
with 2 others
Phase 1/2
3 of 29
1 open now
Registered
17th of 29
by date

Among the 29 studies in Alzheimer Disease by Massachusetts General Hospital, this one is the 10th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2022, is one of 3 in phase 1/2, and was the 17th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

9 of the 29 studies in Alzheimer Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Alzheimer Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.

Read the detailed description

While there are many potential therapeutics being evaluated for Alzheimer's disease and related dementias (ADRD), there is currently no known cure for ADRD and its origin and pathophysiology are still not well understood. However, the association of fibrin with ADRD is becoming increasingly clearer. Up to now it was not possible to quantify brain fibrin in vivo to better elucidate its role in ADRD, but recently, 64Cu-FBP8 was proposed as a tool to detect thrombus anywhere in the body. This unique tool will allow us to non-invasively assess brain fibrin levels in at-risk and ADRD subjects.

The goal of this project is to use 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to assess fibrin levels. It is expected that about 30 people will take part in this research study. 64Cu-FBP8-PET is not currently approved by the U.S. Food and Drug Administration (FDA).

03

Conditions studied

  • Alzheimer Disease
  • Dementia of Alzheimer Type

Keywords

  • Alzheimer Disease
  • Dementia
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 55 and 90 years
  • Ability to provide
  • Specific to healthy volunteers: no history of ADRD
  • Specific to ADRD subjects: clinical diagnosis of AD - either amnestic or atypical, clinical severity ranging from MCI to moderate dementia (CDR 0.5-2.0), score greater than or equal to 15 and/or MOCA greater than or equal to 12
  • Specific to BAnD subjects: referred through the Brain Aging and Dementia (BAnD) research registry

Exclusion criteria

Exclusion Criteria:

  • MR such as: electrical implants such as cardiac pacemakers or perfusion pumps; ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants, ferromagnetic objects such as jewelry or metal clips in clothing
  • Preexisting medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
  • Subjects whose estimated (eGFR) \< 60 mL/min will be excluded from receiving the gadolinium-based contrast agent
  • Research-related radiation exposure exceeding current Massachusetts General Hospital (MGH) Radiology Department guidelines (i.e. 50 millisievert in the prior 12 months)
  • 3. In line with published MGH IRB guidelines for pregnancy must be ruled out by urine ß-HCG if answers to screening questions suggest that pregnancy is possible and if female participants are premenopausal and of child-bearing age. Subjects will not be able to enroll if they are breastfeeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cognitively Normal Subjects and ADRD subjects

    Cognitively Normal Subjects and ADRD subjects

    Diagnostic Test: PET/MR Imaging · Drug: 64Cu-FBP8

Interventions

  • Diagnostic testPET/MR Imaging

    PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol

    Also known as: Positron Emission Tomography/Magnetic Resonance Imaging

  • DrugCopper Cu 64 FBP8Studies of Copper Cu 64 FBP8Copper Cu 64 FBP8 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center

    Also known as: Positron Emission Tomography dye

06

What researchers measure

Primary outcomes

  1. Concentration of fibrin in the brains of ADRD subjects and healthy controls

    64Cu-FBP8-PET will be used to quantify brain fibrin content in the brains of ADRD subjects and healthy controls to evaluate potential regional differences.

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Sep 2026, 53 months after the start.

Of 35 non-industry phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 53 months is above that.

Counting every sponsor, half of 62 studies reached it within 45 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2022
First posted
Apr 20, 2022
StartActual
Mar 29, 2022
Primary completionEst.
Sep 28, 2026
CompletionEst.
Sep 28, 2026
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05336695
Responsible party
Ciprian Catana, MD, PhD (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Apr 20, 2022
Start date
Mar 29, 2022
Primary completion
Sep 28, 2026 (estimated)
Completion
Sep 28, 2026 (estimated)
Last update
Oct 30, 2025

Study contacts

Ciprian Catana, MD, PhD
Contact
ccatana@mgh.harvard.edu
617-643-4885
Ciprian Catana, MD, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Copper Cu 64 FBP8

Start the discussion